Romlusevimab

Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1][2].

Product Specifications

CAS Number

[2509447-08-7]

Product Name Alternative

BRII-198

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/romlusevimab.html

Purity

95.00

Solubility

H2O

Smiles

[Romlusevimab]

Molecular Weight

(145.126 kDa)

References & Citations

[1]Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82 (12) :1327-1331.|[2]Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.